Non-alcoholic fatty liver disease: comparative assessment of diagnostic and treatment approaches in the Russian Federation and People’s Republic of China
Aim of review. To present comparative assessment of diagnostic and treatment approaches at non-alcoholic fatty liver disease (NAFLD) in the Russian Federation and People’s Republic of China. Summary. NAFLD is the leading disease entity among the other chronic liver diseases in the countries of vario...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2018-08-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/193 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860320747126784 |
|---|---|
| author | M. Ch. Semenistaya Fan Jian-Gao O. B. Velichenko Ye. A. Kuznetsova Ch. S. Pavlov |
| author_facet | M. Ch. Semenistaya Fan Jian-Gao O. B. Velichenko Ye. A. Kuznetsova Ch. S. Pavlov |
| author_sort | M. Ch. Semenistaya |
| collection | DOAJ |
| description | Aim of review. To present comparative assessment of diagnostic and treatment approaches at non-alcoholic fatty liver disease (NAFLD) in the Russian Federation and People’s Republic of China. Summary. NAFLD is the leading disease entity among the other chronic liver diseases in the countries of various regions of the world, at the present time it is considered to be one of the main causes for cryptogenic liver cirrhosis development. The pathogenesis of NAFLD closely correlates to both hepatic and cardiovascular involvement that significantly influences both treatment choice and life prognosis. According to the international clinical guidelines, NAFLD screening methods should include elastometry and serological tests to rule out severe liver fibrosis (F> 2). Liver biopsy is carried out at contradictory data of liver elastometry and serological fibrosis markers. Treatment of NAFLD should integrate the range of measures including correction of patients dietic habits and physical activity up to pharmacological treatment. Pharmacotherapy is recommended in the case of nonalcoholic steatohepatitis (NASH) progression (bridging fibrosis ³ F2 and cirrhosis), as well as the earlier stages of NASH with two and more fibrosis progression risk factors (age over 50 years, diabetes mellitus, metabolic syndrome, alanine transaminase elevation). Bicyclol is a drug developed in Materia Medica institute of Academy of medical sciences of China. The study is carried on by Chinese physicians have demonstrated efficacy of the drug for treatment of chronic liver diseases of various etiology, along with its antiinflammatory and antifibrotic properties. The drug registration studies conducted in the Russian Federation revealed high clinical performance of Bicyclol. Conclusion. Etiological and pathogenetic features of NAFLD require diverse therapeutic actions from dietic recommendations and physical activity correction of the prescription of various pharmacological agents. Results of clinical efficacy estimation of the new drug Bicyclol in the Russian market, that it was developed in the People’s Republic of China demonstrate reduction of severity of inflammation, steatosis, fibrosis and decrease of NAFLD activity scores. |
| format | Article |
| id | doaj-art-ff357a5556c84a48894f44d81dd75bd9 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2018-08-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-ff357a5556c84a48894f44d81dd75bd92025-02-10T16:14:29ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732018-08-01276637010.22416/1382-4376-2017-27-6-63-70193Non-alcoholic fatty liver disease: comparative assessment of diagnostic and treatment approaches in the Russian Federation and People’s Republic of ChinaM. Ch. Semenistaya0Fan Jian-Gao1O. B. Velichenko2Ye. A. Kuznetsova3Ch. S. Pavlov4Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical UniversityLiver Cancer InstituteGMP BioscienceFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical UniversityFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical UniversityAim of review. To present comparative assessment of diagnostic and treatment approaches at non-alcoholic fatty liver disease (NAFLD) in the Russian Federation and People’s Republic of China. Summary. NAFLD is the leading disease entity among the other chronic liver diseases in the countries of various regions of the world, at the present time it is considered to be one of the main causes for cryptogenic liver cirrhosis development. The pathogenesis of NAFLD closely correlates to both hepatic and cardiovascular involvement that significantly influences both treatment choice and life prognosis. According to the international clinical guidelines, NAFLD screening methods should include elastometry and serological tests to rule out severe liver fibrosis (F> 2). Liver biopsy is carried out at contradictory data of liver elastometry and serological fibrosis markers. Treatment of NAFLD should integrate the range of measures including correction of patients dietic habits and physical activity up to pharmacological treatment. Pharmacotherapy is recommended in the case of nonalcoholic steatohepatitis (NASH) progression (bridging fibrosis ³ F2 and cirrhosis), as well as the earlier stages of NASH with two and more fibrosis progression risk factors (age over 50 years, diabetes mellitus, metabolic syndrome, alanine transaminase elevation). Bicyclol is a drug developed in Materia Medica institute of Academy of medical sciences of China. The study is carried on by Chinese physicians have demonstrated efficacy of the drug for treatment of chronic liver diseases of various etiology, along with its antiinflammatory and antifibrotic properties. The drug registration studies conducted in the Russian Federation revealed high clinical performance of Bicyclol. Conclusion. Etiological and pathogenetic features of NAFLD require diverse therapeutic actions from dietic recommendations and physical activity correction of the prescription of various pharmacological agents. Results of clinical efficacy estimation of the new drug Bicyclol in the Russian market, that it was developed in the People’s Republic of China demonstrate reduction of severity of inflammation, steatosis, fibrosis and decrease of NAFLD activity scores.https://www.gastro-j.ru/jour/article/view/193неалкогольная жировая болезнь печенифиброзстеатогепатитдиагностикалечениебициклол |
| spellingShingle | M. Ch. Semenistaya Fan Jian-Gao O. B. Velichenko Ye. A. Kuznetsova Ch. S. Pavlov Non-alcoholic fatty liver disease: comparative assessment of diagnostic and treatment approaches in the Russian Federation and People’s Republic of China Российский журнал гастроэнтерологии, гепатологии, колопроктологии неалкогольная жировая болезнь печени фиброз стеатогепатит диагностика лечение бициклол |
| title | Non-alcoholic fatty liver disease: comparative assessment of diagnostic and treatment approaches in the Russian Federation and People’s Republic of China |
| title_full | Non-alcoholic fatty liver disease: comparative assessment of diagnostic and treatment approaches in the Russian Federation and People’s Republic of China |
| title_fullStr | Non-alcoholic fatty liver disease: comparative assessment of diagnostic and treatment approaches in the Russian Federation and People’s Republic of China |
| title_full_unstemmed | Non-alcoholic fatty liver disease: comparative assessment of diagnostic and treatment approaches in the Russian Federation and People’s Republic of China |
| title_short | Non-alcoholic fatty liver disease: comparative assessment of diagnostic and treatment approaches in the Russian Federation and People’s Republic of China |
| title_sort | non alcoholic fatty liver disease comparative assessment of diagnostic and treatment approaches in the russian federation and people s republic of china |
| topic | неалкогольная жировая болезнь печени фиброз стеатогепатит диагностика лечение бициклол |
| url | https://www.gastro-j.ru/jour/article/view/193 |
| work_keys_str_mv | AT mchsemenistaya nonalcoholicfattyliverdiseasecomparativeassessmentofdiagnosticandtreatmentapproachesintherussianfederationandpeoplesrepublicofchina AT fanjiangao nonalcoholicfattyliverdiseasecomparativeassessmentofdiagnosticandtreatmentapproachesintherussianfederationandpeoplesrepublicofchina AT obvelichenko nonalcoholicfattyliverdiseasecomparativeassessmentofdiagnosticandtreatmentapproachesintherussianfederationandpeoplesrepublicofchina AT yeakuznetsova nonalcoholicfattyliverdiseasecomparativeassessmentofdiagnosticandtreatmentapproachesintherussianfederationandpeoplesrepublicofchina AT chspavlov nonalcoholicfattyliverdiseasecomparativeassessmentofdiagnosticandtreatmentapproachesintherussianfederationandpeoplesrepublicofchina |